ArticleHealth physics2014
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Article in Health physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Journal of immunology research · 2016Pooled it
- Biokinetic modelling of the exhalation ofRadiation and environmental biophysics · 2026Article
- Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies.Journal of personalized medicine · 2025Review
- Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis.Frontiers in medicine · 2023Article
- Nanomicelles of Radium Dichloride [Polymers · 2022Article
- Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides.Journal of nuclear medicine technology · 2022Article
- Radium dial workers: back to the future.International journal of radiation biology · 2022Review
- Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [Frontiers in medicine · 2022Review
- Intra-articular use of radium dichloride ([European journal of nuclear medicine and molecular imaging · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Radium-223 dichloride causes transient changes in natural killer cell population and cytotoxic function.International journal of radiation biology · 2021Article
- Development of Targeted Alpha Particle Therapy for Solid Tumors.Molecules (Basel, Switzerland) · 2019Review
- Quantitative measurement ofEJNMMI physics · 2019Article
- Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.American journal of clinical oncology · 2019Review
- Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals.Nuclear medicine and molecular imaging · 2018Review
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2018Article
- Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.AJR. American journal of roentgenology · 2017Review
- Radium 223 dichloride for prostate cancer treatment.Drug design, development and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The majority of patients with late stage castration-resistant prostate cancer (CRPC) develop bone metastases that often result in significant bone pain. Therapeutic palliation strategies can delay or prevent skeletal complications and may prolong survival. An alpha-particle based therapy, radium-223 dichloride (²²³RaCl₂), has been developed that delivers highly localized effects in target areas and likely reduces toxicity to adjacent healthy tissue, particularly bone marrow. Radiation safety aspects were evaluated for a single comprehensive cancer center clinical phase 1, open-label, single ascending-dose study for three cohorts at 50, 100, or 200 kBq kg⁻¹ body weight. Ten patients received administrations, and six patients completed the study with 1 y follow-up. Dose rates from patients administered ²²³Ra dichloride were typically less than 2 μSv h⁻¹ MBq⁻¹ on contact and averaged 0.02 μSv h⁻¹ MBq⁻¹ at 1 m immediately following administration. Removal was primarily by fecal excretion, and whole body effective half-lives were highly dependent upon fecal compartment transfer, ranging from 2.5-11.4 d. Radium-223 is safe and straightforward to administer using conventional nuclear medicine equipment. For this clinical study, few radiation protection limitations were recommended post-therapy based on facility evaluations. Specific precautions are dependent on local regulatory authority guidance. Subsequent studies have demonstrated significantly improved overall survival and very low toxicity, suggesting that ²²³Ra may provide a new standard of care for patients with CRPC and bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.